In fact, siRNA knockdown of type I (IFNAR1 and IFNAR2) and type II (IFNGR2) IFN receptors suggested that both IFN pathways contributed to PDA resistance. This evidence concerns the gene IFNAR1 and Patent ductus arteriosus.